Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Shepherd

Showing results (51-60 of 105) with videos related to

Pageof 11
Sort By:
Diabetes|October 27, 2004
Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention studyNaveed Sattar, Olga Scherbakova, Ian Ford, et al.
Journal of the American College of Cardiology|May 17, 2008
Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgerySanjiv J Shah, David D Waters, Philip Barter, et al.
Journal of Lipid Research|July 7, 2009
Cholesterol absorption and synthesis markers in individuals with and without a CHD event during pravastatin therapy: insights from the PROSPER trialNirupa R Matthan, Nancy Resteghini, Michele Robertson, et al.
Atherosclerosis|March 30, 2007
Effect of pravastatin on the development of diabetes and adiponectin productionToshiyuki Takagi, Morihiro Matsuda, Manabu Abe, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|September 19, 2008
Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets studyDouglas C A Taylor, Ankur Pandya, David Thompson, et al.
Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases|February 7, 2020
Phylogenetic diversity of Mycobacterium tuberculosis in two geographically distinct locations in Botswana - The Kopanyo StudyEleanor S Click, Alyssa Finlay, John E Oeltmann, et al.
Mayo Clinic Proceedings|August 5, 2008
Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney diseaseJames Shepherd, John P Kastelein, Vera A Bittner, et al.
Atherosclerosis|December 17, 2009
Lipoprotein-associated phospholipase A(2), inflammatory biomarkers, and risk of cardiovascular disease in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)Muriel J Caslake, Chris J Packard, Michele Robertson, et al.
Lancet (London, England)|September 12, 2006
Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets studyPrakash Deedwania, Philip Barter, Rafael Carmena, et al.
Circulation|July 16, 2003
Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention StudyNaveed Sattar, Allan Gaw, Olga Scherbakova, et al.
Pageof 11

Showing results (51-60 of 105) with videos related to

Sort By:
Pageof 11
Diabetes|October 27, 2004
Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention studyNaveed Sattar, Olga Scherbakova, Ian Ford, et al.
Journal of the American College of Cardiology|May 17, 2008
Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgerySanjiv J Shah, David D Waters, Philip Barter, et al.
Journal of Lipid Research|July 7, 2009
Cholesterol absorption and synthesis markers in individuals with and without a CHD event during pravastatin therapy: insights from the PROSPER trialNirupa R Matthan, Nancy Resteghini, Michele Robertson, et al.
Atherosclerosis|March 30, 2007
Effect of pravastatin on the development of diabetes and adiponectin productionToshiyuki Takagi, Morihiro Matsuda, Manabu Abe, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|September 19, 2008
Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets studyDouglas C A Taylor, Ankur Pandya, David Thompson, et al.
Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases|February 7, 2020
Phylogenetic diversity of Mycobacterium tuberculosis in two geographically distinct locations in Botswana - The Kopanyo StudyEleanor S Click, Alyssa Finlay, John E Oeltmann, et al.
Mayo Clinic Proceedings|August 5, 2008
Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney diseaseJames Shepherd, John P Kastelein, Vera A Bittner, et al.
Atherosclerosis|December 17, 2009
Lipoprotein-associated phospholipase A(2), inflammatory biomarkers, and risk of cardiovascular disease in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)Muriel J Caslake, Chris J Packard, Michele Robertson, et al.
Lancet (London, England)|September 12, 2006
Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets studyPrakash Deedwania, Philip Barter, Rafael Carmena, et al.
Circulation|July 16, 2003
Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention StudyNaveed Sattar, Allan Gaw, Olga Scherbakova, et al.
Pageof 11